Attovia reels in $105M from crossover investors to run multiple trials of I&I biologics
California biotech Attovia Therapeutics is back with a $105 million Series B just 11 months after unveiling with $60 million.
The Fremont-based startup eyes a series of clinical trials in the crowded inflammation and immunology field with the new money. It will enter human studies in the coming months for its lead program in atopic dermatitis and bring a second biologic into the clinic next year. Overall, the money will bankroll the first two assets through Phase 1 and into Phase 2, as well as take a third discovery program into the clinic, CEO Tao Fu told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
